Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Unveils 
Rare-Diseases Unit

by Lisa M. Jarvis
June 21, 2010 | A version of this story appeared in Volume 88, Issue 25

Taking a page from GlaxoSmithKline’s playbook, Pfizer has created a research unit devoted to finding new medicines to treat rare diseases. A rare or “orphan” disease is defined as one that impacts fewer than 200,000 patients. More than 6,000 diseases are classified as orphan diseases, but less than 10% have dedicated treatments, Pfizer says. GSK established its unit focused on rare diseases in February. The moves come as pharma firms scour the landscape for untapped commercial opportunities.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.